Apellis Pharmaceuticals, Inc. (APLS) Latest Filing Signal

Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Apellis Pharmaceuticals, Inc.'s filing signal turned positive.

Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing treatments for complement-mediated diseases. The company has two marketed drugs: SYFOVRE (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration, and EMPAVELI (pegcetacoplan) for paroxysmal nocturnal hemoglobinuria (PNH), C3 glomerulopathy (C3G), and primary immune complex membranoproliferative glomerulonephritis (primary IC-MPGN). Apellis is also developing a next-generation therapy combining SYFOVRE with APL-3007 for GA and exploring other pipeline candidates. The company's strategy centers on transforming the treatment of GA, maximizing EMPAVELI's impact in rare diseases, and advancing its pipeline by leveraging its complement inhibition expertise.

Revenue is primarily driven by product sales of EMPAVELI and SYFOVRE in the United States, as well as licensing and other revenue from its collaboration with Sobi, which includes product supply and royalties.